
|Articles|January 15, 2005
FDA approval of AMD treatment considered 'a milestone'
On Dec. 17, Eyetech Pharmaceuticals (EYET) announced FDA approval of pegaptanib sodium injection (Macugen) for the treatment of neovascular ("wet") age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
2
Metformin use associated with reduced incidence of intermediate AMD
3
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
4
Sandoz Canada launches aflibercept biosimilar, Enzeevum
5




























